Brian C. Broderick’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$418K Hold
3,310
0.06% 79
2026
Q1
$461K Buy
+3,310
New +$464K 0.09% 76
2018
Q4
Sell
-8,735
Closed -$675K 79
2018
Q3
$675K Sell
8,735
-8,123
-48% -$613K 0.23% 59
2018
Q2
$1.19M Buy
16,858
+35
+0.2% +$2.47K 0.44% 53
2018
Q1
$1.27M Buy
16,823
+418
+3% +$33.2K 0.48% 51
2017
Q4
$1.18M Sell
16,405
-258
-2% -$19.6K 0.43% 54
2017
Q3
$1.35M Sell
16,663
-300
-2% -$22.9K 0.49% 56
2017
Q2
$1.2M Buy
16,963
+160
+1% +$10.6K 0.44% 55
2017
Q1
$1.14M Buy
16,803
+1,320
+9% +$92.8K 0.47% 51
2016
Q4
$1.11M Sell
15,483
-1,125
-7% -$83.6K 0.48% 52
2016
Q3
$1.31M Buy
16,608
+905
+6% +$73.5K 0.56% 49
2016
Q2
$1.31M Buy
15,703
+5,879
+60% +$522K 0.55% 50
2016
Q1
$902K Buy
+9,824
New +$886K 0.39% 57
2015
Q4
Sell
-60
Closed -$6K 102
2015
Q3
$6K Hold
60
﹤0.01% 103
2015
Q2
$7K Hold
60
﹤0.01% 102
2015
Q1
$6K Buy
+60
New +$6.09K ﹤0.01% 104

Other funds holding GILD

Brian C. Broderick's GILD Position: Q2 2026 in Review

Brian C. Broderick held its Gilead Sciences (GILD) position steady in Q2 2026 at 3,310 shares worth $418K. The position accounts for 0.06% of the portfolio, ranked #79.

Brian C. Broderick first reported a position in GILD in Q1 2015 and has held it in 16 quarters since. The position peaked at $1.35M in Q3 2017. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Brian C. Broderick held 3,310 shares of Gilead Sciences worth $418K as of Q2 2026.
  • Brian C. Broderick left its Gilead Sciences share count unchanged in Q2 2026.
  • Gilead Sciences made up 0.06% of Brian C. Broderick's portfolio in Q2 2026, its #79 holding.
  • Brian C. Broderick first reported a position in Gilead Sciences in Q1 2015 and has held it in 16 quarters since.
  • Brian C. Broderick's Gilead Sciences position peaked at $1.35M in Q3 2017.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Brian C. Broderick's 13F filing for Q2 2026, filed 11 Aug 2026.